Tolremo
TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges
- Website
- tolremo.com
- Total Funding
- $17.1M
- Last Round
- $5.9M Extension RoundSep 2023
- Rounds
- 2
About
preventing resistance to cancer therapy
Summary
Tolremo is a Biotech company. It has raised $17.1M in total across 2 rounds, most recently a $5.9M Extension Round round in Sep 2023. Investors include BioMedPartners and Redalpine.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Sep 2023
Sign up to see all 2 rounds
Series A through Extension Round — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/tolremo"><img src="https://indexed.vc/api/badge/company/tolremo" alt="Tolremo on Indexed.vc" width="260" height="76" /></a>